Happy #TrumpTax month!
Since there’s no federally observed months to celebrate in February anymore we should all take some time to enjoy our new, more expensive prices!
@tjsand01@mynamehear@adgirlMM The Priority Review Voucher cost the government nothing, cost taxpayers nothing and stimulated rare disease drug development.
@yago_amat@mynamehear@adgirlMM The Priority Review Voucher was not on the Gabriella Miller bill, it was the Creating Hope Reauthorization act. It did not pass its second extension due to the cuts. It cost taxpayers $0 and was cut with other health programs
@Steveruppert@mynamehear@adgirlMM This is not the priority review voucher. The Creating Hope Reauthorization Act was given an extension from September to 12/20. When the cuts were made this program died with it. It cost taxpayers $0 and incentivizes research for rare diseases.
@NCSwanson@mynamehear@adgirlMM This is not the priority review voucher. Rather, you’ve mentioned an entirely different bill that has nothing to do with the PRV and rare disease research. If you’re going to call me a liar at least figure out what it is that I’m “lying” about.
@larryftmfw1@mynamehear@adgirlMM The Priority Review Voucher was not extended. Beating your chest that I’m a liar because a different bill passed is peak idiocy. Just say you prefer kids with rare diseases to suffer.
@larryftmfw1@mynamehear@adgirlMM I lobbied for the PRVs. They were part of the initial cut from the CR to “get rid of the pork”.
PRVs don’t cost taxpayers a penny.
They incentivize development of rare disease drugs and they did not pass the CR even though there was bipartisan support in Sept to extend.
@HawleyMO@repcleaver@RepSamGraves@Eric_Schmitt
The Priority Review Voucher is set to expire today. Please vote for an extension in the CR. It does not cost taxpayers and gives hope for treatment to children suffering from rare diseases.
Also cut from the congressional bill is the reauthorization of the rare pediatric disease priority review voucher program which helps fund clinical trials & drug development at small companies working on rare diseases. And prescription drug insurance/PBM reform as discussed yesterday